[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"United Immunity, co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100639508","phase-1-phase-12-study-of-ui-102-in-selected-advanced-cancers-100639508",false,"NCT07605962","Phase 1\u002F2 Study of UI-102 in Selected Advanced Cancers","A Phase I\u002FII Open-Label, Dose Escalation, Dose Optimization, and Cohort Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of UI-102, a Novel Cholesteryl Pullulan (CHP) Nanoparticle-formulated TLR7\u002F8 Agonist in Patients With Selected Locally Advanced and\u002For Metastatic Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1,\n* 18 Years and Older (adult, older adult),\n* Histologically confirmed advanced cancer,\n* Archived or fresh tumor tissue sample that must be confirmed as adequate,\n* Evaluable\u002FMeasurable disease per RECIST 1.1,\n* Previously received applicable standard treatments,\n* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control\n\nExclusion Criteria:\n\n* central nervous system metastasis,\n* Ongoing or uncontrolled ascites or pleural effusion,\n* Significant ongoing toxicity from prior anticancer treatment,\n* Out-of-range laboratory values,\n* Clinically significant lung, heart, or autoimmune disease,\n* Ongoing requirement for immunosuppressive treatment,\n* Significant secondary malignancy,\n* Hypersensitivity to study drug or excipients,\n* Pregnant or lactating,\n* Ongoing active infection","ALL","18 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This phase 1\u002F2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7\u002F8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.",[27],"Advanced Cancer",[29,30],"metastatic solid tumors","advanced solid tumors","RECRUITING","2026-06-01",{"date":34,"type":35},"2026-06-03","ACTUAL",{"date":37,"type":35},"2026-05-20",{"date":39,"type":20},"2031-03-31",{"name":41,"class":42},"United Immunity, co., Ltd.","INDUSTRY",3,""]